Newpath Partners

Newpath Partners Newpath Partners was founded in 2018 by Tom Cahill, an MD/PhD physician-scientist who moved into investing. Fund II closed at $350M in December 2021 with a mandate to create life sciences companies, not just fund them. The firm specializes in breakthrough biology platforms. gene editing and regenerative medicine in particular. The portfolio includes 13 companies, with 2 IPOs and 3 acquisitions (Neumora, Metsera, YourBio). The gene editing work is especially interesting: Prime M